Guangzhou Wondfo Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 24, 2022 at 04:57 am
Share
Guangzhou Wondfo Biotech Co.,Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 2,625.28 million compared to CNY 696.61 million a year ago. Revenue was CNY 2,625.28 million compared to CNY 696.61 million a year ago. Net income was CNY 903.51 million compared to CNY 155.42 million a year ago. Basic earnings per share from continuing operations was CNY 2.05 compared to CNY 0.35 a year ago. Diluted earnings per share from continuing operations was CNY 2.05 compared to CNY 0.35 a year ago.
Guangzhou Wondfo Biotech Co Ltd is a China-based company principally engaged in research, manufacture and sales of point-of-care testing (POCT) reagents, POCT instrument and related products. According to the testing result, the Company' products can be divided into qualitative testing products and quantitative testing products. According to the usage, the Company' products include pregnancy testing series, infectious diseases testing series, drugs (drug abuse) testing series and chronic disease testing series. The Company's products are used in POCT, clinical test, field test and personal health management, among others.